Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Recs

0
Player Avatar Bigdog2020 (76.41) Submitted: 7/23/2010 3:04:48 PM : Outperform Start Price: $53.66 BIIB Score: +125.54

Great pipeline - 5 filings over next few years. Nimble size and new leadership will further focus this company and drive continued earnings growth.

Featured Broker Partners


Advertisement